Taken together, these lines of evidence make it likely that inhibitors of the MYB and C/EBPβ transcription factors would have an interesting potential as leads or drugs against leukemia and, possibly, other MYB- or C/EBPβ-dependent tumors. This evidence concerns the gene CEBPB and leukemia.